Table 1 Patient characteristics CAGT no.... | American Society of Hematology

Table 1

Patient characteristics

CAGT no.	Age, y	Sex	Stage at diagnosis	Dose level	Disease burden at CTL infusion	Response at 6 weeks	Best response	GD2 T cells last detected, weeks after infusion	Clinical outcome
1662	9	Male	IV	1	NED	NED	NED	24	NED 11 mo after infusion
1738	5	Male	IV	1	NED	NED	NED	1	NED 10 mo after infusion
1705	4	Male	IV	1	NED	NED	NED	4	NED 10 mo after infusion
1632	20	Female	IIa	1	Relapsed, NED	NED	NED	2	AWD 13 mo after infusion
1629	7	Male	IV	1	Relapsed, NED	NED	NED	12	AWD 7 mo after infusion
1571	4	Female	IV	1	Relapsed, bone lesion	PD	PD	4	DOD 4 mo after infusion
1290	9	Female	IV	1	Relapsed, bone lesion	CR	CR	72	CR 1 yr 9 mo after infusion
1144	4	Female	IV	1	Refractory, bone lesion	PR	CR	192	CR 4 y 10 mo after infusion
1040	10	Male	IV	1	Relapsed, bulky	PD	PD	6	DOD 10 mo after infusion
717	11	Male	IV	1	Relapsed, bulky	PD	PD	1	DOD 2 mo after infusion
1151	10	Female	IV	2	Relapsed, NED	NED	NED	2	DOD 3 y after infusion
1089	4	Female	IV	2	Relapsed, NED	NED	NED	96	NED 3 y 3 mo after infusion
1035	15	Female	IV	2	Relapsed, bone marrow	CR	CR	6	DOD 6 mo after infusion
1117	9	Female	IV	2	Relapsed, bulky	PD	PD	28	DOD 10 mo after infusion
1208	3	Male	IV	2	Relapsed, bulky	SD	SD	12	DOD 6 mo after infusion
1253	9	Female	III	2	Relapsed, bulky	Tumor necrosis	Tumor necrosis	4	DOD 14 mo after infusion
1353	7	Male	IV	3	Relapsed, NED	NED	NED	12	DOD 2 y 7 mo after infusion
1237	4	Female	IV	3	Relapsed, bulky	Tumor necrosis	Tumor necrosis	2	DOD 2 mo after infusion
1361	7	Male	IV	3	Relapsed, bulky	SD	PR	72	AWD 2 y 8 mo after infusion

CAGT no.	Age, y	Sex	Stage at diagnosis	Dose level	Disease burden at CTL infusion	Response at 6 weeks	Best response	GD2 T cells last detected, weeks after infusion	Clinical outcome
1662	9	Male	IV	1	NED	NED	NED	24	NED 11 mo after infusion
1738	5	Male	IV	1	NED	NED	NED	1	NED 10 mo after infusion
1705	4	Male	IV	1	NED	NED	NED	4	NED 10 mo after infusion
1632	20	Female	IIa	1	Relapsed, NED	NED	NED	2	AWD 13 mo after infusion
1629	7	Male	IV	1	Relapsed, NED	NED	NED	12	AWD 7 mo after infusion
1571	4	Female	IV	1	Relapsed, bone lesion	PD	PD	4	DOD 4 mo after infusion
1290	9	Female	IV	1	Relapsed, bone lesion	CR	CR	72	CR 1 yr 9 mo after infusion
1144	4	Female	IV	1	Refractory, bone lesion	PR	CR	192	CR 4 y 10 mo after infusion
1040	10	Male	IV	1	Relapsed, bulky	PD	PD	6	DOD 10 mo after infusion
717	11	Male	IV	1	Relapsed, bulky	PD	PD	1	DOD 2 mo after infusion
1151	10	Female	IV	2	Relapsed, NED	NED	NED	2	DOD 3 y after infusion
1089	4	Female	IV	2	Relapsed, NED	NED	NED	96	NED 3 y 3 mo after infusion
1035	15	Female	IV	2	Relapsed, bone marrow	CR	CR	6	DOD 6 mo after infusion
1117	9	Female	IV	2	Relapsed, bulky	PD	PD	28	DOD 10 mo after infusion
1208	3	Male	IV	2	Relapsed, bulky	SD	SD	12	DOD 6 mo after infusion
1253	9	Female	III	2	Relapsed, bulky	Tumor necrosis	Tumor necrosis	4	DOD 14 mo after infusion
1353	7	Male	IV	3	Relapsed, NED	NED	NED	12	DOD 2 y 7 mo after infusion
1237	4	Female	IV	3	Relapsed, bulky	Tumor necrosis	Tumor necrosis	2	DOD 2 mo after infusion
1361	7	Male	IV	3	Relapsed, bulky	SD	PR	72	AWD 2 y 8 mo after infusion

NED indicates no evidence of disease; PD, progressive disease, CR, complete response; PR, partial response; SD, stable disease; AWD, alive with disease; and DOD, died of disease.